Animal models are routinely employed to assess the treatments for human cancer. However,
due to significant differences in genetic backgrounds, traditional animal models are unable …

Introduction Despite advances in the treatment of acute myeloid leukemia (AML), long-term
survival remains low. In 1994, it was proposed that leukemic stem cells (LSCs) played a key …

CD34 has spear-headed the field of basic research and clinical transplantation since the first
reports of its expression on hematopoietic stem cells (HSCs). Expressed in mice, humans …

Background The interleukin-1 receptor accessory protein (IL1RAP) is highly expressed on
acute myeloid leukemia (AML) bulk blasts and leukemic stem cells (LSCs), but not on …

Despite the considerable progress in acute myeloid leukemia (AML) treatment, relapse after
allogeneic hematopoietic stem cell transplantation (HSCT) is still frequent and associated …

Current medical therapies for treating acute myeloid leukemia (AML) remain unmet, and
AML patients may benefit from targeted immunotherapy approaches that focus on specific …

NK cell responsiveness to target cells is tuned by interactions between inhibitory NK cell
receptors and their cognate HLA class I ligands in a process termed “NK cell education.” …

In this issue of The Lancet Haematology, Matthias Stelljes and colleagues1 present a
compelling exploration of an approach to allogeneic haematopoietic stem-cell …

Fifty percent of AML patients relapse and exhibit poor long-term disease-free survival. This
unmet clinical need is underpinned by the adherence of AML cells in the protective niche of …